R Squared’s Rhythm Pharmaceuticals RYTM Stock Holding History

R Squared’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-780	Closed	-$43.7K	–	1260
2024 Q4	$43.7K	Buy	+780	New	+$43.1K	0.04%	549

Other funds holding RYTM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

R Squared's RYTM Position: Q1 2025 in Review

R Squared sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2025, closing a stake of 780 shares — an estimated $43.7K sold.

R Squared first reported a position in RYTM in Q4 2024 and held it in 1 quarter. The position peaked at $43.7K in Q4 2024. 228 funds tracked by Wall St. Rank hold RYTM as of Q1 2025.

R Squared reported no remaining Rhythm Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 780 Rhythm Pharmaceuticals shares in Q1 2025, an estimated $43.7K.
R Squared first reported a position in Rhythm Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Rhythm Pharmaceuticals position peaked at $43.7K in Q4 2024.
228 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.